At the level of flow cytometry, these cells were HLA-DR+BDCA-2–XCR1–CLEC9A–CD1c+FCER1A+CD32B+AREG+, and their frequency was increased in the CSF compared with PBMCs from each of the 4 MS subjects analyzed (Figure 3H). This evidence concerns the gene CLEC9A and myeloid sarcoma.